Maxim Group Sticks to Their Buy Rating for Actinium Pharmaceuticals (ATNM)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNMResearch Report) yesterday and set a price target of $25.00. The company’s shares closed last Thursday at $8.75.

According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 23.6% and a 44.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.

Actinium Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $43.33, implying a 393.5% upside from current levels. In a report issued on September 21, JonesTrading also initiated coverage with a Buy rating on the stock with a $40.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $19.47 and a one-year low of $4.71. Currently, Actinium Pharmaceuticals has an average volume of 594K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Actinium Pharmaceuticals, Inc. is a clinical-stage, Biopharmaceutical Company focused on developing and potentially commercializing therapies to cell therapies. The firm’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.